The FDA has approved Tabrecta, Novartis for the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. NSCLC is the most common type of lung…
Everything about lung cancer is here.
The FDA has approved Tabrecta, Novartis for the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. NSCLC is the most common type of lung…